ISSN: 1525-4135

Journal Home

Journal Guideline

Journal of Acquired Immune Deficiency Syndromes Q1 Unclaimed

Lippincott Williams and Wilkins Ltd. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Acquired Immune Deficiency Syndromes is a journal indexed in SJR in Infectious Diseases and Pharmacology (medical) with an H index of 171. It has an SJR impact factor of 1,225 and it has a best quartile of Q1. It has an SJR impact factor of 1,225.

Journal of Acquired Immune Deficiency Syndromes focuses its scope in these topics and keywords: hiv, health, viral, infant, expression, women, antiretroviral, therapy, cd, public, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Infectious Diseases (Q1) Pharmacology (medical) (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Journal of Acquired Immune Deficiency Syndromes

1,225

SJR Impact factor

171

H Index

202

Total Docs (Last Year)

872

Total Docs (3 years)

7052

Total Refs

2457

Total Cites (3 years)

797

Citable Docs (3 years)

2.7

Cites/Doc (2 years)

34.91

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Reviews Microbiology Q1
Clinical Microbiology Reviews Q1
The Lancet Infectious Diseases Q1
Cellular and Molecular Immunology Q1
Drug Resistance Updates Q1

Compare this journals

Aims and Scope

Best articles by citations

Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy

Higher Cystatin C Levels Are Associated With Neurocognitive Impairment in Older HIV+ Adults

Implementation and Operational Research

Clinical Utility of Resistance Testing: Retrospective and Prospective Data Supporting Use and Current Recommendations

Effective Approaches for Programming to Reduce Adolescent Vulnerability to HIV Infection, HIV Risk, and HIV-Related Morbidity and Mortality

Pediatric Treatment Scale-Up

Addition of Single-Dose Tenofovir and Emtricitabine to Intrapartum Nevirapine to Reduce Perinatal HIV Transmission

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Addressing Poor Retention of Infants Exposed to HIV

Comparison of Generic Zidovudine + Lamivudine (Cipla, Duovir) and the GlaxoSmithKline Brand (Combivir) Tablets

ERRATUM

Epidemiological Impact of Tenofovir Gel on the HIV Epidemic in South Africa

SHOW MORE ARTICLES

Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics

R211K and L214F Do Not Invariably Confer High Level Phenotypic Resistance to Thymidine Analogs in Zidovudine-Naive Patients With M184V

Microsporidiosis and HIV

Placental Membrane Inflammation and Risks of Maternal-to-Child Transmission of HIV-1 in Uganda

Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP

PrEP Implementation Behaviors of Community-Based HIV Testing Staff

129 Human Endogenous Retrovirus-K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer

PrEP4Love

Prevalence and Route of Transmission of Infection With a Novel DNA Virus (TTV), Hepatitis C Virus, and Hepatitis G Virus in Patients Infected With HIV

Rising Prevalence of HIV-1 Non-B Subtypes in Belgium: 1983???2001

Course of Viral Load Throughout HIV-1 Infection

Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label Observational Study